Grand Angels Raising $25 Million Venture Fund to Fuel Growth of High-Tech Startups
Earlier this month, MVCA Member Grand Angels announced it’s raising a $25 million venture fund to invest in emerging companies in advanced manufacturing, AgTech, life sciences, and software sectors! With the organization’s strong regional focus, university and college relationships, and dedication to growing Michigan’s startup ecosystem, the new fund will help companies connect with the… read more
Grand Angels President Joins ACRE AgTech Board of Directors!
Grand Angels President Tim Parker has joined ACRE AgTech as the newest member of their board of directors! ACRE AgTech is a Michigan-based entrepreneurial support organization that specializes in helping farmers and ag-related entrepreneurs commercialize, license, or sell their ag-technology inventions. Read why Parker chose to join the organization’s board and what excites him about… read more
Research Series Post 1: Is Lack of Seed Stage Capital Hindering Michigan’s Economy?
MVCA is excited to kick off the first post in our research report series! These posts are developed from the findings identified in the 2017 MVCA Research Report. Like last year’s series, we are turning to Michigan’s entrepreneurial and investment community to hear their perspective on a specific trend. This week, we explore the topic of… read more
Grand Angels Recognizes Jody Vanderwel for Leadership
Grand Angels Spring Reception and Dinner celebrates Jody Vanderwel for 12 years of leadership in Michigan’s entrepreneurial and investment community. Grand Angels Spring Reception began with networking over cocktails followed by opening remarks from newly appointed Grand Angels President, Tim Parker. Vanderwel was recognized for her leadership and dedication that has been instrumental to the… read more
HistoSonics Appoints Mike Blue as CEO and Board Member; Completes First Close of a Series B Financing
This week, HistoSonics announced that Mike Blue joined the company as President, CEO, and board member of HistoSonics. Additionally, the company closed a Series B financing round of $8.3 million led by MVCA members Venture Investors, LLC, Wolverine Venture Fund and Grand Angels. ANN ARBOR, Mich., March 13, 2017 – HistoSonics, Inc. announced today that Mike… read more
Grand Angels Gets New President Amid Growing Activity
Tim Parker to Lead Michigan’s Leading Angel Network, Organization Deploys $3.5 Million during 2016 HOLLAND, Mich., November 16, 2016,— MVCA member Grand Angels, Michigan’s leading angel investment network today announced Timothy Parker has become the organization’s second president in the 13-year history of the organization. Parker officially succeeded Jody Vanderwel, following a unanimous vote of the… read more
Legislative Alert: House Tax Policy Committee Set to Vote on Early Stage (Angel) Investment Bills This Week
House Tax Policy Committee Chairman, Jeff Farrington (R-30) wasted no time getting a hearing on two bills that make up an Angel Investment Program he introduced during the one day this summer that the House was in session. He quickly moved to have House Bills 5786 and 5787 placed in his committee to shepherd them… read more
From Startup to Public Company: ProNAi Therapeutics is a Michigan Success Story
The road from company formation to successful exit is a tenuous one, even when the startup is well-capitalized and quickly finds a profitable niche in the marketplace. For a biotech company developing drug therapies, their survival to test the drug safety and efficacy for many years, sometimes a decade or more, is highly dependent on… read more
Michigan Venture Capital Association’s statewide tour visits in Grand Rapids
West Michigan’s angel and venture investment community came together to examine the Michigan Venture Capital Association’s (MVCA) Annual Report on venture capital activity in Michigan. The event offered participants a deep dive into the report’s findings, with particular focus on the venture community’s impact on West Michigan. Maureen Miller Brosnan, executive director of MVCA, told… read more
ProNAi Therapeutics Raises $59.5M Series D Round for Phase II Clinical Trials
ProNAi Therapeutics Inc . has collected $59.5 million after clinical studies showed that its lead drug could help non-Hodgkin’s lymphoma patients who are running out of options.